PolyPid strikes $320M-plus deal with Azurity to launch SSI drug in US/Canada
PolyPid disclosed a collaboration with Azurity Pharmaceuticals to commercialize its SSI drug in the U.S. and Canada, potentially yielding more than $320 million in milestones and royalties. Details on timing and structure were not provided. The arrangement broadens PYPD's commercialization scope and could lift near-term revenue opportunities if milestones are achieved.
View signal analysis